$COO (The Cooper Companies Inc.)

$COO {{ '2016-09-02T08:58:28+0000' | timeago}} • Webcast

$COO reported that CooperSurgical is executing some initiatives to strengthen its business. The initiatives include transitioning to a geographic sales model, adding sales reps in under-penetrated areas, launching products in new markets and increasing focus on high growth areas.

$COO {{ '2018-01-04T21:58:01+0000' | timeago}} • Announcement

$COO declared a semi-annual dividend of $0.03 per share, payable on February 9, 2018, to stockholders of record on January 23, 2018.

$COO {{ '2017-12-08T14:45:01+0000' | timeago}} • Webcast

$COO said the Procornea and Paragon acquisitions are part of its specialty lens business. These two businesses combined are expected to bring in about $30MM in revenues. The company believes the specialty lens business is growing in the upper single-digit, if not double-digit range. $COO is optimistic about the growth of this business in future.

$COO {{ '2017-12-08T14:43:23+0000' | timeago}} • Webcast

$COO recently purchased an existing manufacturing facility in Costa Rica for its CooperSurgical business to consolidate a significant portion of its global manufacturing. $COO has made progress upgrading the facility and hiring employees and plans to begin production of the Wallace Transfer Catheter in the near future.

$COO {{ '2017-12-08T14:43:09+0000' | timeago}} • Webcast

$COO's CooperVision business posted 4Q17 revenues of $439MM, up 7% as reported and up 5% pro forma. Daily silicone hydrogel lenses drove growth up 37% in constant currency. The CooperSurgical business posted revenues of $123MM, up 15% as reported and up 7% pro forma. Fertility drove growth up 28% as reported.

$COO {{ '2017-12-07T22:13:57+0000' | timeago}} • Infographic

$COO The Cooper Companies, Inc. Earnings AlphaGraphic: Q4 2017 Highlights

$COO {{ '2017-12-07T22:03:28+0000' | timeago}} • Announcement

For FY18, $COO expects revenues to be $2.48-2.53Bil. Adjusted diluted EPS is expected to be $11.35-11.65.

$COO {{ '2017-12-07T22:03:06+0000' | timeago}} • Announcement

$COO reported an increase in 4Q17 earnings. Net income was $88.6MM or $1.78 per share compared to $60.5MM or $1.23 per share in 4Q16. Adjusted EPS was $2.65 in 4Q17. Revenue increased 8% YoY to $561.5MM.

$COO {{ '2017-09-11T20:51:49+0000' | timeago}} • Announcement

Medical devices company $COO has signed an agreement with pharma firm $TEVA to acquire the global rights and business of Teva’s Paragard Intrauterine Device for $1.1Bil in cash. The transaction, which is likely to close prior to the end of the calendar year, is expected to be accretive to Cooper's earnings by $0.7-0.75 per share in the first year.

$COO {{ '2017-08-31T20:33:38+0000' | timeago}} • Announcement

$COO expects its 4Q17 total revenue in the range of $552-565MM and its non-GAAP EPS in the range of $2.60-2.70. The company predicts CooperVision revenue in the range of $435-445MM and CooperSurgical revenue to be in the range of $117-120MM for 4Q17.

$COO {{ '2017-08-31T20:31:46+0000' | timeago}} • Announcement

$COO lifted its FY17 total revenue outlook to $2.129-2.142Bil from $2.110-2.135Bil and its non-GAAP EPS guidance to $9.66-9.76 from $9.50-9.65. The company also raised its FY17 CooperVision revenue estimate to $1.67-1.68Bil from $1.645-1.665Bil, while lowering its CooperSurgical revenue forecast to $459-462MM from $465-470MM.

$COO {{ '2017-08-31T20:31:29+0000' | timeago}} • Announcement

$COO reported a jump in 3Q17 earnings driven by favorable product mix and currency within CooperVision as well as improved margins at CooperSurgical from successful integration activity. Net income rose to $103.6MM or $2.09 per share from $87.9MM or $1.79 per share last year. Sales grew 8% to $556MM. Non-GAAP EPS increased 15% to $2.64.

$COO {{ '2017-07-06T20:48:37+0000' | timeago}} • Announcement

$COO has declared a semi-annual dividend of 3 cents per share, payable on August 7, 2017, to stockholders of record on July 21, 2017.

$COO {{ '2017-06-02T11:34:54+0000' | timeago}} • Webcast

$COO stated that on the consumer purchasing trend, the company is seeing solid trends. The biggest driver in the marketplace continues to be the trading up, which means taking the existing consumer base and moving it from the two-week modality into primarily the one-day modality.

$COO {{ '2017-06-02T11:11:33+0000' | timeago}} • Webcast

$COO expects 3Q17 EPS to be slightly lower than 4Q17 due to lower sequential GM at CooperVision. This 3Q17 reduction is due to inventory turns every six months and production level declines in Dec. and Jan. due to annual manufacturing shutdowns to upgrade and retool $COO's plants.

$COO {{ '2017-06-02T11:02:51+0000' | timeago}} • Webcast

$COO's operating expenses grew 8.8% in 2Q17, slightly above the reported revenue growth of 8%. This was driven by investments such as additional sales personnel, along with expenses from acquisition. Operating income growth however was strong, up 18.9%, driven by gross margin improvements. Operating margins grew 2.5% YoY to 26.8%.

$COO {{ '2017-06-02T10:51:59+0000' | timeago}} • Webcast

$COO commented that in the contact lens market overall, the company grew its share two times the market or 10% against the market growth of 5% in calendar first quarter. Geographically, $COO grew 8% in the Americas, 10% in EMEA and 16% in Asia-Pacific.

$COO {{ '2017-06-01T20:38:07+0000' | timeago}} • Announcement

$COO lifted its FY17 total revenue outlook to $2.110-2.135Bil from $2.09-2.13Bil and its non-GAAP EPS guidance to $9.50-9.65 from $9.10-9.30. The company also raised its FY17 CooperVision revenue estimate to $1.645-1.665Bil from $1.62-1.65Bil, while lowering its CooperSurgical revenue forecast to $465-470MM from $470-480MM.

$COO {{ '2017-06-01T20:37:42+0000' | timeago}} • Announcement

$COO reported a jump in 2Q17 earnings driven by higher sales as well as favorable currency and product mix within CooperVision led by Biofinity. Net income rose to $104.9MM or $2.12 per share from $74.1MM or $1.52 per share last year. Net sales grew to $522.4MM from $483.8MM. Non-GAAP EPS increased to $2.50 from $2.05.

$COO {{ '2017-03-21T20:58:25+0000' | timeago}} • Announcement

$COO's Board of Directors has approved a $500MM increase in the company's share repurchase program. The share repurchase program now totals $1Bil and has approximately $618.5MM of remaining availability with no expiration date.

$COO {{ '2017-03-02T21:42:24+0000' | timeago}} • Announcement

$COO said that during 1Q17, CooperVision segment continued gaining market share driven by growth in Biofinity and daily silicone hydrogel products while CooperSurgical segment continued its growth driven by fertility.

Recent Transcripts

COO (The Cooper Companies Inc.)
Thursday, December 7 2017 - 10:00pm
MDT (Medtronic plc)
Tuesday, November 21 2017 - 1:00pm
CNCE (Concert Pharmaceuticals, Inc.)
Thursday, November 9 2017 - 1:30pm
VRML (Vermillion, Inc.)
Wednesday, November 8 2017 - 9:30pm
STAA (STAAR Surgical Company)
Wednesday, November 8 2017 - 9:30pm
HOLX (Hologic Inc.)
Wednesday, November 8 2017 - 9:30pm
CCXI (ChemoCentryx, Inc.)
Tuesday, November 7 2017 - 10:00pm
ATRS (Antares Pharma Inc.)
Tuesday, November 7 2017 - 1:30pm
TFX (Teleflex Incorporated)
Thursday, November 2 2017 - 12:00pm
STE (Steris Plc)
Wednesday, November 1 2017 - 2:00pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
PFE (Pfizer Inc.)
Tuesday, October 31 2017 - 2:00pm
MRK (Merck & Co. Inc.)
Friday, October 27 2017 - 12:00pm
CELG (Celgene Corporation)
Thursday, October 26 2017 - 1:00pm
LH (Laboratory Corp. of America Holdings)
Wednesday, October 25 2017 - 1:00pm
ISRG (Intuitive Surgical, Inc.)
Thursday, October 19 2017 - 8:30pm
ABT (Abbott Laboratories)
Wednesday, October 18 2017 - 1:00pm
JNJ (Johnson & Johnson)
Tuesday, October 17 2017 - 12:30pm
COO (The Cooper Companies Inc.)
Thursday, August 31 2017 - 9:00pm
MDT (Medtronic plc)
Tuesday, August 22 2017 - 12:00pm

AlphaGraphics you may like